As of Tuesday, December 23, Burning Rock Biotech Limited’s BNR share price has dipped by 9.53%, which has investors questioning if this is right time to buy.
The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...
TrinScreen HIV order signals renewed strength in global HIV testing market- Company also reports a key milestone of Adjusted EBITDA1positive ...
The company said, “The Company remains committed to pursuing immediate growth opportunities that are both profitable and supported by its ...
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical util
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2025 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, ann ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback